Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22189977 | 0.76 | SLC7A5 (0.41) | HDAC1HDAC6HDAC8LMNA | |
| SCHEMBL8955938 | 0.73 | HSD17B10 (0.41) | LMNA | |
| SCHEMBL22190003 | 0.67 | PDE10A (0.50) | CDK5CDK5R1L3MBTL1 | |
| SCHEMBL10662585 | 0.66 | LOXL2 (0.55) | LMNA | |
| SCHEMBL9706349 | 0.65 | HDAC1 (0.49) | HDAC1HDAC6HDAC8LMNA | |
| SCHEMBL1983877 | 0.65 | HDAC1 (0.49) | HDAC1HDAC6HDAC8LMNA | |
| SCHEMBL22190025 | 0.65 | CDK5 (0.54) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL22190056 | 0.63 | HDAC6 (0.53) | HDAC6 | |
| SCHEMBL28797485 | 0.62 | APAF1 (0.51) | L3MBTL1 | |
| SCHEMBL8120297 | 0.62 | NOS3 (0.43) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | CDK5 2074/4885CDK5R1 2306/4885CCNA2 2273/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | CDK5 1516/4885CDK5R1 1956/4885CCNA2 2238/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CDK5 2074/4885CDK5R1 2306/4885CCNA2 2273/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CDK5 2074/4885CDK5R1 2306/4885CCNA2 2273/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | CDK5 2302/4885CDK5R1 2663/4885CCNA2 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.